Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD

References

• LimKE, KimSR, KimHK, KimSR. Symptom clusters and quality of life in subjects with COPD. Respir Care. 2017;62:1203–1211. doi:10.4187/respcare.0537428720670
   PubMed Web of Science ®Google Scholar
• Díaz-GuzmanE, ManninoDM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:7–16. doi:10.1016/j.ccm.2013.10.00224507833
   PubMed Web of Science ®Google Scholar
• MiravitllesM, SorianoJB, García-RíoF, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64:863–868. doi:10.1136/thx.2009.11572519553233
   PubMed Web of Science ®Google Scholar
• World health organization (WHO), 2019. Global Health Observatory (GHO) data. Mortality and global health estimates. Available from: https://www.who.int/gho/mortality_burden_disease/en/. Accessed 6, 2019
   Google Scholar
• MiravitllesM, RiberaA. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017a;18:67. doi:10.1186/s12931-017-0548-328431503
   PubMed Web of Science ®Google Scholar
• Casas-MendezF, AbadíasMJ, YugueroO, et al. Treatment strategies after acute exacerbations of chronic obstructive pulmonary disease: impact on mortality. PLoS One. 2018;13:e0208847. doi:10.1371/journal.pone.020884730550602
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, CrinerGJ, MartínezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53:128–149. doi:10.1016/j.arbres.2017.02.00128274597
   PubMed Web of Science ®Google Scholar
• SinghD, AgustiA, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):pii: 1900164. doi:10.1183/13993003.00164-2019
   Web of Science ®Google Scholar
• MiravitllesM, Soler-CataluñaJJ, CalleM, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017b;53:324–335. doi:10.1016/j.arbres.2017.03.01828477954
   PubMed Web of Science ®Google Scholar
• Calle RubioM, Rodríguez HermosaJL, Soler-CataluñaJJ, et al. Medical care according to risk level and adaptation to Spanish COPD guidelines (GesEPOC): the epoconsul study. Arch Bronconeumol. 2018;54:270–279. doi:10.1016/j.arbres.2017.11.01529361320
   PubMed Web of Science ®Google Scholar
• IzquierdoJL, MiravitllesM, EsquinasC, et al. Characteristics of COPD patients managed in respiratory medicine departments in Spain, according to GOLD groups and GesEPOC clinical phenotypes. Arch Bronconeumol. 2018;54:559–567. doi:10.1016/j.arbres.2018.03.02129853257
   PubMed Web of Science ®Google Scholar
• KhanR, Socha-DietrichK Investing in medication adherence improves health outcomes and health system efficiency: adherence to medicines for diabetes, hypertension, and hyperlipidaemia. OECD Health Working Papers. No. 105. OECD Publishing:Paris Available from: https://www.oecd-ilibrary.org/docserver/8178962c-en.pdf?expires=1571733795&id=id&accname=guest&checksum=E01A3272F1055DE80E6FE325648B4CE3. Accessed 6, 2019
   Google Scholar
• HumenbergerM, HornerA, LabekA, et al. Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD). BMC Pulm Med. 2018;18:163. doi:10.1186/s12890-018-0724-330340565
   PubMed Web of Science ®Google Scholar
• RestrepoRD, AlvarezMT, WittnebelLD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:371–384. doi:10.2147/COPD.S303618990964
   PubMedGoogle Scholar
• GeorgeM. Adherence in asthma and COPD: new strategies for an old problem. Respir Care. 2018;63:818–831. doi:10.4187/respcare.0590529794213
   PubMed Web of Science ®Google Scholar
• KardasP, LewekP, MatyjaszczykM. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91. doi:10.3389/fphar.2013.0009123898295
   PubMed Web of Science ®Google Scholar
• MäkeläMJ, BackerV, HedegaardM, LarssonK. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107:1481–1490. doi:10.1016/j.rmed.2013.04.00523643487
   PubMed Web of Science ®Google Scholar
• KingD, ZhangS, RosenV, IsmailaAS Single versus multiple inhalers in patients with chronic obstructive pulmonary disease (COPD): a systematic literature review. Poster PMD17. Presented at: ISPOR European Congress; 114–8; 2017; Glasgow.
   Google Scholar
• Van BovenJF, ChavannesNH, van der MolenT, et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108:103–113. doi:10.1016/j.rmed.2013.08.04424070566
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJA, CalverleyPM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939–943. doi:10.1136/thx.2009.11366219703830
   PubMed Web of Science ®Google Scholar
• ChrystynH, SmallM, MilliganG, et al. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108:358–365. doi:10.1016/j.rmed.2013.09.02124209768
   PubMed Web of Science ®Google Scholar
• IsmailaA, CorriveauD, VaillancourtJ, et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr Med Res Opin. 2014;30:1427–1436. doi:10.1185/03007995.2014.90882824666181
   PubMed Web of Science ®Google Scholar
• Farmaindustria. Plan de adherencia al tratamiento. Uso responsable del medicamento; 2016 Available from: http://www.farmaindustria.es/adherencia/. Accessed 4, 2019
   Google Scholar
• Rutten-van MölkenMP, OostenbrinkJB, MiravitllesM, MonzBU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ. 2007;8:123–135. doi:10.1007/s10198-007-0039-417370096
   PubMed Web of Science ®Google Scholar
• Rutten-van MölkenMP, GoossensLM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012;30:271–302. doi:10.2165/11589270-000000000-0000022409290
   PubMed Web of Science ®Google Scholar
• Lopez-BastidaJ, OlivaJ, AntoñanzasF, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010;24:154–170. doi:10.1016/j.gaceta.2009.07.01119959258
   PubMed Web of Science ®Google Scholar
• Puig-JunoyJ, Oliva-MorenoJ, Trapero-BertránM, et al. Guía y recomendaciones para la realización y presentación de evaluaciones económicas y análisis de impacto presupuestario de medicamentos en el ámbito del CatSalut. Barcelona: Servei Català de la Salut (CatSalut); 2014.
   Google Scholar
• Instituto Nacional de Estadística (INE). Estadistica del padrón continuo. Datos provisionales a 1 de enero de 2018. Available from: www.ine.es. Accessed 4, 2019
   Google Scholar
• SorianoJB, MiravitllesM, BorderíasL, et al. Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors. Arch Bronconeumol. 2010;46:522–530. doi:10.1016/j.arbres.2010.06.00820832926
   PubMed Web of Science ®Google Scholar
• Real Patient Data – Big Pac. Pacientes en tratamiento farmacológico para la EPOC. Movimiento Total Anual (MAT) a Q2 2018. Real Life Data SLU. Available from: www.rlifedata.com. Accessed 4, 2019
   Google Scholar
• Observatorio de adherencia al tratamiento (OAT). Estudio Nacional de la adherencia al tratamiento en patologías crónicas. Available from: https://www.oatobservatorio.com/. Accessed 4, 2019
   Google Scholar
• PlazaV, López-ViñaA, EntrenasLM, et al. Differences in adherence and non-adherence behaviour patterns to inhaler devices between COPD and asthma patients. COPD. 2016;13:547–554. doi:10.3109/15412555.2015.111844926788620
   PubMedGoogle Scholar
• IQVIA. Pharmaceutical market database. Triple therapies sales, 2019 (data on file). Available from: https://www.iqvia.com/. Accessed July 8, 2020.
   Google Scholar
• YuAP, GuérinA, Ponce de LeonD, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14:486–496.21679019
   PubMedGoogle Scholar
• ToyEL, BeaulieuNU, McHaleJM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435–441. doi:10.1016/j.rmed.2010.09.00620880687
   PubMed Web of Science ®Google Scholar
• BotPlus 2.0. Drug database of the general council of pharmaceutical colleges. Portalfarma. Available from: https://botplusweb.portalfarma.com/. Accessed 4, 2019
   Google Scholar
• Ministry of Health. Royal decree-law 8/2010. Extraordinary measures to reduce the public deficit. Boletín Oficial del Estado; 2010 Available from: http://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf. Accessed 4, 2019
   Google Scholar
• BaumgartnerPC, HaynesRB, HersbergerKE, ArnetI. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290. doi:10.3389/fphar.2018.0129030524276
   PubMed Web of Science ®Google Scholar
• MiravitllesM, GáldizJB, HuertaA, et al. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis. 2016;11:123–132. doi:10.2147/COPD.S9400626848262
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística (INE). Índice de Precios de Consumo. Available from: www.ine.es. Accessed 4, 2019
   Google Scholar
• GisbertR, BrosaM Healthcare costs database: eSalud. Barcelona: Oblikue Consulting, S.L Available from: http://www.oblikue.com/bddcostes/. Accessed 3, 2019
   Google Scholar
• MiravitllesM, HuertaA, Fernández-VillarJA, et al. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Health Qual Life Outcomes. 2014;12:120. doi:10.1186/s12955-014-0120-525189786
   PubMed Web of Science ®Google Scholar
• Van BovenJF, RyanD, EakinMN, et al. Enhancing respiratory medication adherence: the role of health care professionals and cost-effectiveness considerations. J Allergy Clin Immunol Pract. 2016;4:835–846. doi:10.1016/j.jaip.2016.03.00727587317
   PubMed Web of Science ®Google Scholar
• KarampitsakosT, HillasG2, ZervasE, et al. Prospective evAluatIon foR inhalation devices in Greek patients with COPD and asthma: the PAIR study. Pulm Pharmacol Ther. 2020;60:101882. doi:10.1016/j.pupt.2019.10188231881275
   PubMed Web of Science ®Google Scholar
• DarbàJ, RamírezG, García-RiveroJL, et al. Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease in Spain. Clinicoecon Outcomes Res. 2017;9:127–137. doi:10.2147/CEOR.S12530128228660
   PubMed Web of Science ®Google Scholar
• IsmailaAS, BirkR, ShahD, et al. Once-daily triple therapy in patients with advanced COPD: healthcare resource utilization data and associated costs from the FULFIL trial. Adv Ther. 2017;34:2163–2172. doi:10.1007/s12325-017-0604-x28875459
   PubMed Web of Science ®Google Scholar
• LaiCC, ChenCH, LinCYH, et al. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2019;14:1539–1548. doi:10.2147/COPD.S20084631371939
   PubMed Web of Science ®Google Scholar
• MiravitllesM, SicrasA, CrespoC, et al. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting. Ther Adv Respir Dis. 2013;7:139–150. doi:10.1177/175346581348408023653458
   PubMed Web of Science ®Google Scholar
• MerinoM, VilloroR, Hidalgo-VegaÁ, CarmonaC. Social economic costs of COPD in Extremadura (Spain): an observational study. Int J Chron Obstruct Pulmon Dis. 2018;13:2501–2514. doi:10.2147/COPD.S16735730174420
   PubMed Web of Science ®Google Scholar